865. The problem of Late-Onset CMV
Session: Symposium: Management of Difficult Infections in the Late Post-Transplant Period
Saturday, October 22, 2011: 10:45 AM
Room: 210ABC
Cytomegalovirus (CMV) is one of the most important infectious complications of organ and tissue transplantation. It leads to direct morbidity related to febrile and organ invasive syndromes, while also increasing the risk of indirect complications such as rejection, allograft failure, and poor overall graft and patient survival. Prevention of CMV disease is with antiviral prophylaxis or preemptive therapy. The practice of antiviral prophylaxis has led to the emergence of late onset CMV disease. This presentation will describe the epidemiology, clinical features, risk factors, treatment, and outcome of late onset CMV disease in transplant recipients.


Raymund Razonable, MD, Mayo Clinic, Rochester, MN

Dr. Raymund R Razonable is Associate Chair for Faculty Development and Diversity in the Division of Infectious Diseases, and Director of Transplant Infectious Diseases at the Mayo Clinic in Rochester, MN. He is Associate Professor of Medicine at the College of Medicine, at the Mayo Clinic in Rochester, Minnesota. After graduating with honors as Doctor of Medicine, Dr. Razonable pursued training in Internal Medicine at the Beth Israel Hospital in New York and later in Infectious Diseases at the Mayo Graduate School of Medicine. During his training, he received awards of distinction, including the Alexander Award as the Most Outstanding Medical Resident and the Geraci Award for the Most Outstanding Infectious Disease Fellow. Dr. Razonable’s clinical and research interests are centered on orthopedic infections and transplant infections. He has published over 130 original and review articles, book chapters, and other manuscripts in the field of infectious diseases. Dr. Razonable has served as a reviewer for over 20 medical and scientific journals and is currently editor of Transplant Infectious Diseases, member of the Editorial Advisory Board of the Journal of Infectious Diseases and has served in panels that develop national and international guidelines for the management of infections. Dr. Razonable is currently a member of the American Society for Microbiology, Infectious Disease Society of America, Immunocompromised Host Society, the Transplantation Society, and the American Society of Transplantation.



Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.